ReviewClinical immunology (Orlando, Fla.)2021
Natural killer cells play an important role in virus infection control: Antiviral mechanism, subset expansion and clinical application.
Review in Clinical immunology (Orlando, Fla.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Pooled it
- Identifying SARS-CoV-2 'memory' NK cells from COVID-19 convalescent donors for adoptive cell therapy.Immunology · 2022Trial
- Immunological profiles of natural killer cells and their subpopulations in overweight and obesity class-I individuals stratified by two-dimensional categories of lipid profiles and body mass index.Biomedical reports · 2026Article
- Natural killer cells against viral infection: from basic biology to immunotherapy.Precision clinical medicine · 2026Review
- Immune dysregulation in type 2 diabetes mellitus: Implications for tuberculosis, COVID-19, and HIV/AIDS.Infectious medicine · 2025Review
- NK Cells: A Powerful Squad Versus SARS-CoV-2.International journal of molecular sciences · 2025Review
- Review
- Advancing Natural Killer Cell Therapy: Genetic Engineering Strategies for Enhanced Cancer Immunotherapy.Annals of laboratory medicine · 2025Review
- Novel drug targets for monkeypox: From viral to host proteins.Infectious medicine · 2025Article
- Article
- Bronchoalveolar lavage single-cell transcriptomics reveals immune dysregulations driving COVID-19 severity.PloS one · 2025Article
- GMP Manufacturing of Allogenic iPSC-NK Cells for Immunotherapy.Advances in experimental medicine and biology · 2025Review
- NK cells modulate in vivo control of SARS-CoV-2 replication and suppression of lung damage.PLoS pathogens · 2024Article
- Buccal Administration of a Zika Virus Vaccine Utilizing 3D-Printed Oral Dissolving Films in a Mouse Model.Vaccines · 2024Article
- The role of CD56Journal of neuroinflammation · 2024Review
- Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS.Pathogens (Basel, Switzerland) · 2023Review
- Epstein-Barr virus reactivation correlates with worse outcomes for patients exposed to hepatitis B virus after haploidentical hematopoietic stem cell transplantation.Annals of hematology · 2023Article
- Prospects of Cytomegalovirus-Specific T-Cell Receptors in Clinical Diagnosis and Therapy.Viruses · 2023Review
- Saponins of North Atlantic Sea Cucumber: Chemistry, Health Benefits, and Future Prospectives.Marine drugs · 2023Review
- Insight into the liver dysfunction in COVID-19 patients: Molecular mechanisms and possible therapeutic strategies.World journal of gastroenterology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the global spread of coronavirus disease 2019 (COVID-19), the important role of natural killer (NK) cells in the control of various viral infections attracted more interest, via non-specific activation, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and activating receptors, as well as specific activation, such as memory-like NK generation. In response to different viral infections, NK cells fight viruses in different ways, and different NK subsets proliferate. For instance, cytomegalovirus (CMV) induces NKG2C + CD57 + KIR+ NK cells to expand 3-6 months after hematopoietic stem cell transplantation (HSCT), but human immunodeficiency virus (HIV) induces KIR3DS1+/KIR3DL1 NK cells to expand in the acute phase of infection. However, the similarities and differences among these processes and their molecular mechanisms have not been fully discussed. In this article, we provide a summary and comparison of antiviral mechanisms, unique subset expansion and time periods in peripheral blood and tissues under different conditions of CMV, HIV, Epstein-Barr virus (EBV), COVID-19 and hepatitis B virus (HBV) infections. Accordingly, we also discuss current clinical NK-associated antiviral applications, including cell therapy and NK-related biological agents, and we state the progress and future prospects of NK cell antiviral treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.